% | $
Quotes you view appear here for quick access.

CalAmp Corp. Message Board

quicktwosmile 59 posts  |  Last Activity: Jun 30, 2016 5:16 PM Member since: Oct 18, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Its Official....PXLW is in the Verizon Tablet

    by quicktwosmile Jun 30, 2016 5:07 PM
    quicktwosmile quicktwosmile Jun 30, 2016 5:16 PM Flag

    IR was correct......the dots connected !

  • quicktwosmile quicktwosmile Jun 30, 2016 5:15 PM Flag

    Just Like I stated back on June 19....that the chip WAS in the Verizon just confirmed it 10 minutes ago.......

    It seem that they wanted to start Q3 with some they waited until after Q2 ended to make the official announcement.......

    IR told me to connect the dots and sure enough........the dots connected !!!!!!!!!!!!!!!!!!!

  • SAN JOSE, Calif.--(BUSINESS WIRE)-- Pixelworks, Inc.(PXLW) , an innovative provider of display processing technology, today announced that Verizon Wireless and ASUS have launched the ZenPad Z8, incorporating Pixelworks’ Iris mobile display processor with True Clarity® technology. The 7.9” ASUS tablet leverages Pixelworks’ mobile video processing technology to deliver 60 million pixel optimizations per second for blur-free motion, establishing a new standard for HDTV quality in mobile video.

    "The ZenPad Z8 is the ultimate entertainment device for watching movies, TV shows, and live sports," said Rangoon Chang, ASUS General Manager, Mobile Computing Business Unit. “And ASUS’ VisualMaster suite of picture enhancements, driven by Pixelworks’ True Clarity technology, is the key to a remarkably enjoyable viewing experience.”

    “Pixelworks’ technology is setting a new standard for delivering superior video quality on mobile devices, and in doing so is providing OEMs with a truly unique opportunity to differentiate their products,” said Richard Miller, Pixelworks(PXLW) Executive Vice President. “We’re very pleased to expand our relationship with ASUS, and having the ZenPad Z8 available exclusively through Verizon Wireless represents another leading product that showcases the benefits of Pixelworks’ True Clarity video processing technology.”

    In addition to the benefits provided by Pixelworks’ Iris video processor, the ASUS ZenPad Z8 features the following:
    7.9” screen with a 2048x1536 resolution display
    Qualcomm® Snapdragon™ 650 Hexa Core, 1.8 GHz
    Supports Verizon’s 4GLTE network, and ready for XLTE
    2GB of RAM, 16GB of storage, up to 128GB of expandable storage
    8-MP rear-facing, 2-MP front-facing camera
    USB type-C connector
    The Pixelworks Iris family of mobile display processors implements the Company’s True Clarity algorithms, processing every video pixel at up to 60 frames per second. This ensures that users’ video experience remains true to the content creation

  • Reply to

    BJ's response to the trial timeline in Japan.

    by quicktwosmile Jun 23, 2016 9:42 AM
    quicktwosmile quicktwosmile Jun 23, 2016 9:52 AM Flag

    He responded quickly....within a hour ....yesterday

  • I asked him a question on this topic and got a email seems what pushes the timelime out to 2018 is the " possible " 9 MONTH REVIEW PROCESS that the PMDA " could " take to decide whether to give conditional or final approval.

    BJ Lehmann

    Jun 22 at 4:15 PM

    Dear Mr. ***********,

    There was nothing stated in the Annual meeting that has not been previously stated publicly in recent presentations.

    As you know, Japan has a special regulatory approval process for Regenerative Medicine therapies, such as cell therapies like MultiStem. This allows for contingent approval based on a showing of safety and evidence of efficacy, and with such approval, a company could market its therapy, with a commitment to complete additional studies to confirm efficacy. This means that a single stroke study in Japan could lead to such approval and commercialization. Additionally, PMDA actions suggest that if the evidence for efficacy is strong enough, then full approval might also be possible, meaning no additional clinical studies might be required. Healios has upsized the study, as you have noted, to strengthen the efficacy data set, and to enable it to have an opportunity for both accelerated conditional approval and full approval. And, as you have noted, it has committed to having more sites to mitigate the timing impact of having more patients in the study.

    Healios will start its study as soon as it has final PMDA approval, noting that there have already been many interactions with the PMDA, so a couple months from now or so. Enrollment could take a year or more or less, and if the study is a success, that would be followed by the application process (applying for contingent or full approval to market) which typically takes 9 months or so in Japan, as I understand it. Healios will update the markets over the next months, at which point, point, we can communicate with more clarity to SH.

  • quicktwosmile quicktwosmile Jun 19, 2016 5:26 PM Flag does.

    Read the description....and compare the specs stated to the specs on the Asus table that had the PXLW chip in it last year...

    The ZenPad Z8 is a Verizon exclusive that attempts to inject some life into the staid 7.9-inch tablet form factor. In particular, the carrier is calling the Z8 "a multimedia powerhouse" thanks to a Qualcomm Snapdragon 650 hexacore processor (also used in Xiaomi's Redmi Note 3 phablet), pair of front-facing speakers, and the Asus VisualMaster suite of image-enhancing technologies.

    Those enhancements, which include Tru2Life technology for sharpness optimization and intelligent contrast adjustment, were touted when Asus rolled out the ZenPad Z300M and Z380M tablets last month. But whereas those ZenPads were saddled with a pedestrian 1,280x800 screen, the Z8 sports a higher-res 2,048x1,536 display. It offers an 8-megapixel rear-facing camera (along with a 2-megapixel front-facing webcam) as opposed to the 5-megapixel one in the Z300M and Z380M, though they all share Asus' PixelMaster tech to enhance photo quality.

    The Tru2life technology says....Pixleworks inside !!!

  • quicktwosmile quicktwosmile Jun 19, 2016 5:21 PM Flag


    Spoke to investor relations...and although he could NOT say definatively....he said investors would be keen....To connect the dots....Ergo..YES .

  • I have never seen such a bunch of inept idiots in charge of a company that is traded on Nasdaq......

    They dont even hold Quarterly Conference calls....which they could use to update their investors !!!

    Complete MORONS run this company !!!!!

  • Insiders
    (SEC Form 4)

    # of Open Market Buys
    4 4

    # of Sells
    0 0

    Total Insider Trades

    Last 3 mo

    3 Mo.
    # of Shares Bought

    # of Shares Sold
    0 0

    Total Shares Traded

    Net Activity

    Trades in last 3 months: 4
    Trades in last 12 months: 4
    The Summary totals only include Open Market Buys, the table below Includes all purchases.

    Click on the column header links to resort ascending (▲) or descending (▼).

    CARUSO JAMES V Officer 04/20/2016 46,948@ 2.1200
    BERNS PAUL L Director 04/20/2016 117,371 @ 2.1200
    NEIS JOHN Director 04/20/2016 Buy.......indirect 234,742 @ 2.1200
    HILL STEPHEN A Director 04/20/2016 Buy...... direct 9,390 @ 2.1200

  • Meso down 42% overseas on the ASX exchange last night, Healios down ready for anything today on ATHX.....

    I think they made it worse by delaying the news soooo long !!!

  • quicktwosmile quicktwosmile Jun 13, 2016 9:43 PM Flag

    Go to Google finace and type in ticker MSB and it will pull up Mesoblast stock trading downunder......

  • Meso ticker MSB trading on the ASX exchange is off 20% with Healios also down 15% in Japan.....the Asian markets are off early across the board.......

    ATHX might see some pressure as the sector is selling off.....SanBio is off 10%.....

  • quicktwosmile by quicktwosmile Jun 13, 2016 6:37 PM Flag

    June 13 (Reuters) - Mesoblast Ltd(MESO) on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries(TEVA).

    While Teva returned its rights to the potential blockbuster treatment without any financial payment, the Israel-based generic drugmaker can still benefit from any eventual success as one of Mesoblast's top shareholders. Teva inherited about 14 percent of the Australian company through its acquisition of Cephalon and has assisted in development of the therapy.

    "The operational support we received from Teva has been excellent," Mesoblast Chief Executive Silviu Itescu said in a telephone interview.

    Teva, through Cephalon, held about 60 percent of the rights to the therapy. Teva's current strategy did not include further pursuing the heart failure treatment, known as MPC-150-IM, Itescu said.

    "We're very pleased to have regained the asset. We will drive the program," Itescu said.

    A Credit Suisse report last month forecast peak sales of $4.1 billion for the heart failure treatment.

    The company said it expects to complete its pivotal 600-patient Phase III trial by the end of next year.

    An independent data monitoring committee found no safety issues and strongly recommended continuing the study after reviewing data from the first 175 patients, Mesoblast said. The trial is designed to show that the treatment can significantly reduce heart failure hospitalizations and deaths.

    Mesoblast said it has the financing to complete the clinical trial, but will seek a large company partner to help sell the treatment, if approved.

    "For sales and marketing, we will be partnering with a major cardiovascular company that has an existing sales force and commitment to the heart failure field," Itescu said.

    He added that the company has already been in preliminary talks with potential partners.

    Chronic heart failure is a debilitating progressive disease in which the heart becomes enlarged and increasingly unable to sufficiently pump blood to the rest of the body.

    Mesoblast uses a specialized type of adult stem cells to create an "off-the shelf" product that could be used in many patients. (Reporting by Bill Berkrot; Editing by David Gregorio)

    (c) Copyright Thomson Reuters 2016. Click For Restrictions -

  • quicktwosmile by quicktwosmile Jun 13, 2016 9:30 AM Flag

    Mesoblast suspension puts Teva links in the crosshairs

    Date June 13, 2016 - 6:24PM
    Brian Robins

    Mesoblast chief executive Silviu Itescu's substantial stake in the company has taken a hammering.
    Mesoblast chief executive Silviu Itescu's substantial stake in the company has taken a hammering. Photo: Josh Robenstone

    The forced sale of assets by Israeli-based pharmaceutical group Teva has triggered speculation its longstanding research programs with local biotechnology company Mesoblast may be on the block, or simply given back to the company.

    Mesoblast sought a suspension in the trading of its shares on the sharemarket last week, subsequently extending the suspension to Friday morning, with the length of the suspension causing concern.

    "The signs are that it is bad news, with the company scrambling to limit the downside," one industry analyst said.

    Teva has been reported to seeking to divest as much as $US2 billion in assets – double the original estimate – as it seeks regulatory approval for the $US40 billion purchase of a generic drug portfolio from the UK's Allergan. Along with an estimated 50 drugs that are already on the market, another 25 drugs under development ranging from cancer to respiratory disease and central nervous system disorders, could also be sold.

    Teva is also under pressure to slash borrowings with the purchase. Mesoblast has longstanding links with Teva, which is funding some of its key clinical trials, in particular a high-profile trial to treat chronic heart failure, with concerns that Mesoblast would be forced to slash research and development spending due its high cash burn.

    "If it is handed back, our survival analysis indicates Mesoblast has 1.1 years of cash left," says David Blake of Bioshares.

    Mesoblast has begun to slow spending in

  • quicktwosmile quicktwosmile Jun 6, 2016 1:50 PM Flag

    Yes....I am sure a upgrade came in last month...

  • Reply to

    Bearish forecast....unlikely?

    by gatto64it May 20, 2016 12:21 PM
    quicktwosmile quicktwosmile Jun 3, 2016 2:13 PM Flag

    No.....I am Long CCXI and CARA and ATHX....

    I like the prospects that each of those 3 companies possess......AND none of those needs to raise money in the forseeable future and they have important trials in the works AND have partnerships in place....

    Those r my plays right now.....

  • quicktwosmile quicktwosmile Jun 3, 2016 12:10 PM Flag

    This is a VERY hard stock to try and get a SHORT term direction on......just when you think its going higher, it TANKS.....and when you its going to roll over and tank....then Strength comes out of no-where and pushes it higher.....

    I am sticking with the Long Term trend.....which is HIGHER since the Vifor 85 million partnership agreement and the 3 insider buys at $4.05 !!!!!!!!!!!!!

  • epvantageDOTcom/Universal/View.aspx?type=Story&id=642350&isEPVantage=yes

    Not every application resulted in Prime status, though – far from it. Of the 18 hopefuls since the scheme was launched in March, the EMA rejected 14.

    It did not name names, but published a list of the therapeutic areas and indications they are involved in – and this suggests that KTE-C19 was not so lucky in the other NHL subtypes.

    Since April 6, the agency has received a further 14 applicants for Prime, and it plans to give a monthly update on the programme

  • Reply to

    added more at $4.80

    by quicktwosmile Jun 1, 2016 1:58 PM
    quicktwosmile quicktwosmile Jun 2, 2016 2:30 PM Flag

    Thanks ....I couldnt believe it fell that much yesterday.....congrats on getting cheap shares to you too !!!

  • Reply to

    Did TEVA just dump MESO for ATHX???

    by unemonl Jun 1, 2016 3:24 PM
    quicktwosmile quicktwosmile Jun 1, 2016 6:41 PM Flag

    This is right from Meso Web Site....

    The securities of Mesoblast Limited (the “Company”) will be placed in Trading Halt Session State at the
    request of the Company, pending the release of an announcement by the Company. Unless ASX decides
    otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of
    normal trading on Friday, 3 June 2016 or when the announcement is released to the market

14.20-0.18(-1.25%)Jul 29 4:00 PMEDT